Currently, CSF and positron emission tomography (PET) biomarkers, including Aβ, tau, and neurofilament light chain (NfL), are employed for the prediction of dementia onset and progression from mild cognitive impairment (MCI) to AD [187,188]. The gene discussed is MAPT; the disease is Alzheimer disease.